TuHURA Biosciences And Kintara Therapeutics Announce Agreement For Potential Acquisition Of Kineta's Anti-VISTA Antibody
TuHURA Biosciences And Kintara Therapeutics Announce Agreement For Potential Acquisition Of Kineta's Anti-VISTA Antibody
TuHURA生物科技与kintara therapeutics宣布达成协议，可能收购Kineta的抗VISTA抗体。
- KVA12123 is a rationally targeted, anti-VISTA antibody checkpoint inhibitor to reverse VISTA immune suppression and remodel the tumor microenvironment (TME) to overcome acquired resistance to immunotherapies
- KVA12123 is currently in a Phase 1/Phase 2 clinical study as a monotherapy and in combination with Merck's anti-PD1 therapy, KEYTRUDA (pembrolizumab), in patients with advanced solid tumors
- To date, KVA12123 has demonstrated a favorable clinical safety and tolerability profile observed with no dose limiting toxicities and no evidence of Cytokine Release Syndrome (CRS) associated toxicities at doses examined
- Concurrent $5 million investment from existing TuHURA shareholder preserves TuHURA's strong balance sheet for advancing its IFx-2.0 Phase 3 accelerated approval trial and novel bi-functional ADCs
- KVA12123是一种有理靶向的抗VISTA抗体检查点抑制剂，用于扭转VISTA免疫抑制并重塑肿瘤微环境（TME），以克服对于免疫疗法的获得性耐药性
- KVA12123目前正在一项1/2期临床研究中作为单一治疗方法和与默沙东的抗PD1疗法KEYTRUDA（pembrolizumab）联合用于晚期实体瘤患者。
- 到目前为止，KVA12123已经证明了良好的临床安全性和耐受性，观察到没有剂量限制的毒性和无细胞因子释放综合征（CRS）相关毒性
- 现有的TuHURA股东同时进行500万美元的投资，保持强大的资产负债表，推进其IFx-2.0 3期快速批准试验和新型双重嵌合物ADCs（抗体药物复合物）的研发。